NCT05394064: An ongoing trial by SwanBio Therapeutics, Inc.
This trial is ongoing. It must report results 6 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05394064 |
|---|---|
| Title | A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients With Adrenomyeloneuropathy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 17, 2022 |
| Completion date | June 30, 2025 |
| Required reporting date | June 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |